title: Colorectal cancer in 2014: progress in defining first-line and maintenance therapies.
abstract: The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.
authors.affiliation: Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Joleen M
authors.initials: JM
authors.lastname: Hubbard
authors.affiliation: Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
authors.forename: Axel
authors.initials: A
authors.lastname: Grothey
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D006801:Humans; D011364:Professional Practice / Q000639:trends; D016879:Salvage Therapy / Q000379:methods / Q000639:trends
chemical_list: D000970:Antineoplastic Agents